MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
3. Government_Funders & Regulators
*Government: International
Europe
*Europe: Regions
*Western Europe
United Kingdom_UK (England, Scotland, Wales, Northern Ireland)
*Industry: United Kingdom - UK (England, Scotland, Wales, Northern Ireland)
Syntaxin
Parents
*Architects: Neurology, Psychology, Mental Health, CNS, Pain & TBI Companies (Pharmaceuticals, Drugs, Biotechnology, Biosimilars)
*Industry: United Kingdom - UK (England, Scotland, Wales, Northern Ireland)
Venture Capital: Series C
Children
Participants include Lundbeckfond Ventures, Ipsen, Seventure Partners, Abingworth, SROne, Life Science Partners, Johnson & Johnson Development Corp and Quest for Growth.
Syntaxin (United Kingdom) a preclinical-stage biopharmaceutical company focusing on targeted secretion inhibitors for the potential treatment of pain, endocrine disease and cancer, closed a $28.3M Series C financing.
Syntaxin, Ltd.: Series C $28.3M (2010)